Calluna Pharma SRL
Calluna Pharma reported total assets of 73,235 € at the end of the 2025 financial year (annual accounts filed with the NBB on 22 Jun 2026).
The score of Calluna Pharma shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity -45 % Total assets -47 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Calluna Pharma's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | −32,468 € | ||||
| Equity | 70,251 € | ||||
| Cash | 65,996 € | ||||
| EBITDA | −32,564 € | ||||
| Total assets | 73,235 € |
Filed annual accounts
- Year ended 31 Dec 2025filed on 22 Jun 2026
- Year ended 31 Dec 2024filed on 24 Jun 2025
- Year ended 31 Dec 2023filed on 18 Jun 2024
- Year ended 31 Dec 2022filed on 03 Jul 2023
- Year ended 31 Dec 2021filed on 30 Jun 2022
Calluna Pharma's financial analysis
- Solvency95.9%sector median: 56.0%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Calluna Pharma
Calluna Pharma's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0866.397.070
- VAT number
- BE0866397070
- Peppol
- Registered · 0208:0866397070 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 16 Jul 2004
- Registered office
- 2322 Hoogstraten
- Latest accounts
- 2025 · filed on 22 Jun 2026
- Activity
- Manufacture of basic pharmaceutical products (NACE 21100)
Calluna Pharma (SRL) has been based in Hoogstraten since 2004, active in: manufacture of basic pharmaceutical products. For 2025, it reports a net loss of 32,468 € and equity of 70,251 €; its revenue is not published. Its solvency stands at 95.9%, above the median of its sector (56.0%).
Companies similar to Calluna Pharma
Companies in the same business, of comparable size and area, outside its group.
- CFG Pharma Manufacture of basic pharmaceutical products Courcelles · balance sheet 50,919 €
- Premium Pharma Retail Manufacture of basic pharmaceutical products Molenbeek-Saint-Jean · balance sheet 34,216 €
- Superbiotics Manufacture of other food products n.e.c. Éghezée · balance sheet 183,984 €
- MDT Services & Technologies Manufacture of basic pharmaceutical products Lontzen · balance sheet 102,386 €
- Pharmacie Courouble Manufacture of basic pharmaceutical products Schaerbeek · balance sheet 129,672 €
- Pranarom MED Manufacture of basic pharmaceutical products Ath · balance sheet 24,820 €
- Clarethis Manufacture of basic pharmaceutical products Soignies · balance sheet 172,781 €
- Dierenartsen Hond en Kat Manufacture of pharmaceutical preparations Deinze · balance sheet 321,318 €
Frequently asked questions about Calluna Pharma
What is the revenue of Calluna Pharma?
Calluna Pharma files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Calluna Pharma?
In Belgium, the VAT number is the company number prefixed with BE: BE0866397070 for Calluna Pharma, if the company is VAT-registered. Its company number (CBE) is 0866.397.070.
Where is the registered office of Calluna Pharma?
According to the CBE register, the registered office of Calluna Pharma is in 2322 Hoogstraten.
What is the equity of Calluna Pharma?
At the close of the 2025 financial year, the equity of Calluna Pharma amounts to 70,251 €, a solvency of 95.9% of total assets.
Who manages Calluna Pharma?
The register lists 2 active mandates at Calluna Pharma. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Calluna Pharma
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →